Eton Pharmaceuticals (NASDAQ:ETON) Given New $80.00 Price Target at Canaccord Genuity Group

Eton Pharmaceuticals (NASDAQ:ETON) had its price target upped by analysts at Canaccord Genuity Group from $68.00 to $80.00 in a report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target would suggest a potential upside of 39.49% from the stock’s current price.

Several other brokerages have also recently issued reports on ETON. HC Wainwright increased their target price on Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Craig Hallum reissued a “buy” rating and issued a $78.00 price target on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. B. Riley Financial restated a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Finally, Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $77.00.

Eton Pharmaceuticals Stock Up 21.6%

Shares of NASDAQ ETON traded up $10.20 during midday trading on Friday, reaching $57.35. 879,979 shares of the company’s stock traded hands, compared to its average volume of 448,599. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 151.17 and a beta of 0.89. The stock’s 50 day simple moving average is $54.92 and its 200-day simple moving average is $36.26. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. The company had revenue of $57.93 million during the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. On average, analysts predict that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 4,166 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the sale, the insider directly owned 43,381 shares in the company, valued at $2,388,991.67. This trade represents a 8.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the transaction, the director directly owned 59,745 shares in the company, valued at $3,529,137.15. This represents a 45.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 79,166 shares of company stock valued at $4,809,672. 16.49% of the stock is owned by insiders.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ETON. Hilton Head Capital Partners LLC purchased a new position in Eton Pharmaceuticals during the 3rd quarter worth $26,000. Sterling Capital Management LLC increased its position in Eton Pharmaceuticals by 845.7% during the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock valued at $46,000 after buying an additional 795 shares in the last quarter. Toth Financial Advisory Corp acquired a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $43,000. USA Financial Formulas acquired a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $62,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Eton Pharmaceuticals in the third quarter valued at about $75,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Record sales and earnings beat: Q3 product sales reached $57.9 million, up 158% year over year and above analyst expectations of about $42 million. Eton reported GAAP diluted EPS of $1.06 and non-GAAP diluted EPS of $0.50, both ahead of estimates. Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Raised 2026 guidance: Management now expects revenue above $175 million, up from its prior forecast of more than $145 million, and adjusted EBITDA above 40% of revenue, versus more than 35% previously. The company also said it exceeded its $200 million annualized revenue-run-rate goal five quarters ahead of schedule. Eton Pharma jumps after Q3 beat and guidance hike
• Positive Sentiment: Higher analyst target: HC Wainwright raised its price target from $70 to $80 and reiterated a Buy rating, signaling a more optimistic view of Eton’s prospects. HC Wainwright stock recommendations
• Neutral Sentiment: Pipeline update: Eton announced preliminary results from an ET-700 pilot study evaluating copper absorption inhibition and gastrointestinal tolerability; the headline did not provide enough detail to assess the findings’ potential impact. Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.